NCT02512926 2025-10-15
POE14-01
Stanford University
Phase 1 Completed
Clinical Trials
7 trialsNCT01336920 2023-09-15
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
Phase 1 Completed
NCT02293109 2022-03-10
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
University of California, Davis
Phase 1 Completed
NCT02145403 2022-01-03
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT01372540 2019-07-16
Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01137747 2016-06-14
AML ALL
Washington University School of Medicine
Phase 1 Completed
NCT01212380 2016-05-09
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
Phase 1 Completed